Gene therapy for ARVC with PKP2 mutation
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed PKP2 gene mutation (the kind that causes ARVC).
- You must have a diagnosis of ARVC based on the 2010 Task Force Criteria.
- Your heart's left ventricle must pump at least 50% of the blood out (called LVEF ≥50%).
- You must have an implantable cardiac defibrillator (ICD) that can send data to your doctor, and it must have been in place for at least 9 months.
- You must be in NYHA heart failure class I, II, or III (meaning you can be active with some limits).
- You must have frequent premature ventricular contractions (PVCs) as measured by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
This study looks at how exercise affects heart rhythm in people with ARVC, a genetic heart condition. Participation involves supervised exercise sessions and heart monitoring to better understand safe activity levels.
This study follows people with a confirmed PKP2 genetic mutation and arrhythmogenic cardiomyopathy (ACM) to understand how their condition changes over time. It may help doctors learn more about the disease and plan future treatments.
This Phase 1 trial tests RP-A601 (a gene-delivery type treatment) to see if it can reduce dangerous heart rhythm problems in people with PKP2-related arrhythmogenic cardiomyopathy (ACM). Because it’s an early safety/dose study, the main goal is to check safety and how the body responds.
This trial tests a new gene therapy called SGT-501 for people with a genetic heart condition called CPVT, which can cause dangerous fast heartbeats. The goal is to see if the treatment can reduce these episodes.
This trial tests a one-time gene therapy for people with heart failure who still have normal pumping strength (preserved ejection fraction). It aims to improve how heart cells handle calcium, which may help the heart relax better and ease symptoms.
Hear when a new Arrhythmogenic Right Ventricular Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.